Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Common Equity (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Common Equity for 12 consecutive years, with $183.8 million as the latest value for Q1 2026.

  • For Q1 2026, Common Equity rose 709.55% year-over-year to $183.8 million; the TTM value through Mar 2026 reached $183.8 million, up 709.55%, while the annual FY2025 figure was $203.0 million, N/A changed from the prior year.
  • Common Equity hit $183.8 million in Q1 2026 for Crescent Biopharma, down from $203.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $203.0 million in Q4 2025 and bottomed at -$30.2 million in Q1 2025.
  • Average Common Equity over 5 years is $67.3 million, with a median of $51.5 million recorded in 2022.
  • On a YoY basis, Common Equity climbed as much as 9058.6% in 2025 and fell as far as 204.32% in 2025.
  • Crescent Biopharma's Common Equity stood at $42.9 million in 2022, then fell by 10.52% to $38.4 million in 2023, then tumbled by 103.39% to -$1.3 million in 2024, then skyrocketed by 15692.32% to $203.0 million in 2025, then fell by 9.44% to $183.8 million in 2026.
  • According to Business Quant data, Common Equity over the past three periods came in at $183.8 million, $203.0 million, and $116.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.